Please login to the form below

Not currently logged in
Email:
Password:

ShangPharma hires Biogen exec

Art Taveras joins as chief scientific officer 

ShangPharma, Art Taveras ShangPharma has hired Biogen Idec's Dr Art Taveras as president and chief scientific officer.

Dr Taveras held several vice president roles at US-based biotech Biogen, including for small molecules drug discovery, chemistry R&D and CMC development.

He now moves to China to head science at ShangPharma, a clinical research organisation (CRO) which employs 2,000 scientists.

"His extensive leadership, strategic and technical experience at the highest levels in pharmaceutical drug discovery and development will be a great asset to the company as it strives to become the preferred small molecules and biologics drug discovery partner for biopharmaceutical companies,” said Michael Hui, chairman and CEO of ShangPharma.

Dr Taveras' career prior to joining Biogen includes senior positions at Alantos Pharmaceuticals and Schering-Plough.

28th October 2013

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...